SQ 28603

Drug Profile

SQ 28603

Latest Information Update: 28 Nov 1994

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihypertensives; Heart failure therapies
  • Mechanism of Action Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 28 Nov 1994 Discontinued-Preclinical for Heart failure in USA (Unknown route)
  • 26 Nov 1994 Discontinued-Preclinical for Hypertension in USA (Unknown route)
  • 26 Nov 1994 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top